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Abstract
Background: Canine atopic dermatitis is an allergic inflammatory skin disease common in West Highland white
terriers. A genome-wide association study for atopic dermatitis in a population of West Highland white terriers
identified a 1.3 Mb area of association on CFA17 containing canine protein tyrosine phosphatase non-receptor type
22 (lymphoid) PTPN22. This gene is a potential candidate gene for canine atopic dermatitis as it encodes a
lymphoid-specific signalling mediator that regulates T-cell and possibly B-cell activity.
Findings: Sequencing of PTPN22 in three atopic and three non-atopic West Highland white terriers identified 18
polymorphisms, including five genetic variants with a bioinformatically predicted functional effect. An intronic
polymorphic repeat sequence variant was excluded as the cause of the genome-wide association study peak
signal, by large-scale genotyping in 72 West Highland white terriers (gene-dropping simulation method, P = 0.01).
Conclusions: This study identified 18 genetic variants in PTPN22 that might be associated with atopic dermatitis in
West Highland white terriers. This preliminary data may direct further study on the role of PTPN22 in this disease.
Large scale genotyping and complementary genomic and proteomic assays would be required to assess this
possibility.
Findings
Canine atopic dermatitis (AD) is an allergic inflammatory
skin disease that is common in West Highland white ter-
riers (WHWTs) [1]. Following a genome-wide associa-
tion (GWAS) in a group of related WHWTs, we found a
1.3 Mb area on CFA 17 which was significantly asso-
ciated with the disease [2]. Based on its biological func-
tions, expression patterns and proximity to this area of
association, PTPN22 was selected as a candidate gene for
AD in this population. This gene encodes a lymphoid tyr-
osine phosphatase (PTPN22), a signalling mediator that
regulates generic and specialised immune functions in
mammals [3]. Activation of T and B lymphocytes is a key
event in the pathogenesis of atopic disease [4], and the
disruption of these pathways could cause hyper-reactive
pathogenic T-cell responses, as well as affect B-cell
selection, maturation and function [5,6]. In humans and
dogs, genetic variants in the gene PTPN22 have been
associated with auto-immune diseases [7-9]. In humans,
these include psoriasis, a chronic immune-mediated
inflammatory skin disease that shares susceptibility loci
with human AD [10,11]. To date, no association has been
found between PTPN22 variants and atopic disease in
humans [12].
The University of Queensland Animal and Human
Ethics Committees, and the University of Sydney Animal
Ethics Committee approved this study. Written consent
was obtained from all participating dog owners.
Criteria used to classify dogs in the present study are
described elsewhere [1]. Fourteen set of primers were
designed with primer3 [13], to sequence a total of 12.6
Kb of PTPN22 in 14 PCR products (Table 1). Amplifica-
tion reactions used the HotStar HiFidelity PCR Kit
(QIAGEN Pty Ltd, Doncaster, Vic, Australia) and 0.5
μM (PCR products 5 and 12), 1.5 μM (6 and 14) or 1
μM (remaining PCR products) of primers; at 55°C (PCR
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any medium, provided the original work is properly cited.Table 1 Primer sequences used to amplify and sequence 12.6 Kb of canine PTPN22 in three atopic and three non-atopic WHWTs
PCR
product
Forward amplification
primer
Reverse amplification primer Internal forward sequencing
primer
Internal reverse sequencing
primer
Predicted gene
region
Product
size
1 CCTCATCAGGTGCTCTTCGT GGTTTTGCCTCTCTCCCTTC TGAAGTGGAAGAGTCTCAGAGC AGAAAAGGCAGAAGGCCAGT 5’UTR, exon 1 1041
2 GGCTCTGTCCTGAATTGGAG TCTGCCCTTACCAGGACACT - - Exons 2,3 858
3 CCAAATAAGAGGTCGGGGTA CTACTGGGAAAATGGGCAAA AGAAAAGGGAAGGAAGGACA TCTGTCCTTCCTTCCCTTTTC Exons 4,5 863
4 ACCACAGTTGACCTTGGATAA AGATGAAGGCACATCATGGTC - ACATCAAAGGTCCCCTACTCC Exons 6,7 1182
5 CCACTTGAACTGGTGAAGCA ACCAGTCCTTCCACAACCAG - GGATGGAACCCCATATTGAA Exons 8 1172
6 TGCTCTGGGAAGTAGGGATG CAAGGCAAGGGACATAGGAA AATCCACCACAACCAAACCT AGCCCGTATTTCCAACTTCC Exons 9,10 1267
7 CCGAAATGAGGTAGGCAAAC GCCCTGTCACTCACCCTTAT - - Exons 11 483
8 TGGAAACTCACCTCTTTTGTGA TTCTTTGAGAAGGAAAAGGAAGAA CAGAGTGGGAGACAAAAGCA CCAGCTCCTTGGTGTCTCTC Exons 12,13 1296
9 GAAGCAGCAGAAAACCTCCTA ACCCCACATCCTCTAGCACA GATCCCCATTTGCATTGTTC TGGCCCAATTCTTAGGAGTGT Exons 14,15 889
10 GGGTAAAGGATGCGTTTTCA TGGGAGCTATTATGGGAACC - - Exons 16 332
11 TGAGGCTCCAGTTATGGTTCA CAGTCTTGTTCTCAATCTGCTTC AAGTGGGACCTAAATGGAAAAG CCTTTTCCATTTAGGTCCCACT Exons 17,18 747
12 GGATGGGAAAAAGTAGCAAGG TTCTGATACAAAGAGCCATAGCA - - Exon 19 410
13 TTCCCTTTAGTGTTGGGCTTT TTGGCTTTGGCTAGTCACATT - - Exon 20 92
14 GGCTGAATTACCAAAGGTTGT TTCACAAATCCATCGTCAGG TCGCAAAATCTGACTTGTGG GGGAGATGTGCAAGGAATTT Exon 21, 3’UTR 550
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6Table 2 PTPN22 sequence variants identified by sequencing genomic DNA from three atopic and three non-atopic WHWTs.
Sequence
variant
identity
Position
on CFA17
(bp)
a,b
Predicted
location in
gene
Nucleotide in
reference
database
b
Sequence
of variant
Reference
SNP identity
Predicted
functional effect
c
Variant
risk
score
c
Atopic dogs Non-atopic dogs Cross-species
conservation of variant
nucleotide sequence
b,d
Dog 1 Dog 2 Dog 3 Dog
4
Dog 5 Dog
6
1 54759173 UTR C T rs22597162 Transcription
regulatory (score
86.5)
1-3 C/C C/T C/T C/C C/C C/C Conserved in 10/10
2 54759006 UTR A del New variant
(dbSNP ss
315790492)
Transcription
regulatory (score
87.7)
1-3 del/del del/A del/A T/A del/A A/A Conserved in 9/10
3 54742593 Intronic A G rs22597162 NA 0-2 G/G G/A G/A G/G G/G G/G Not conserved
4 54742027 Intronic A T rs22559551 NA 0-2 T/T T/A T/A A/A T/A A/A Conserved in 6/10
5 54739568 Intronic T C rs22559538 NA No risk T/T C/T C/T C/C C/T C/C Not conserved
6 54739315 Intronic A G New variant
(dbSNP ss
315790493)
NA 0-2 G/G G/G G/G A/A A/G A/A Not conserved
7 54738923 Intronic G del New variant
(dbSNP ss
15790494)
NA No risk del/del del/del del/del del/
del
del/del del/
del
NA
8 54738927 Intronic - A New variant
(dbSNP ss
315790495)
NA No risk A/A A/A A/A A/A A/A A/A NA
9 54734456 Intronic T C rs22559532 NA 0-2 C/C C/T C/T C/C C/C C/C Not conserved
10 54734415 Intronic A G rs22559522 NA No risk A/A A/G A/G G/G A/G G/G Conserved in 10/10
11 54717953 Exonic G A New variant
(dbSNP ss
315790496)
Synonymous
Splicing regulatory
(score 85.4)
1-4 G/G G/G G/G A/A A/A A/A Conserved in 7/10
12 54715779 Intronic T C rs22578128 NA 0-2 C/C C/T C/T T/T C/T T/T Conserved in 2/10
13 54709793 Intronic
(spice site)
17-T repeat
(wild)
22-T
repeat
(variant)
New variant
(dbSNP ss
315790497)
Alternative
splicing regulatory
(score 3.39)
3-4 variant/
variant
variant/
wild
variant/
wild
wild/
wild
variant/
wild
wild/
wild
Conserved in 10/10
14 54699432 UTR C T New variant
(dbSNP ss
315790498)
NA 0-2 C/C C/C C/C T/T T/T T/T Not conserved
15 54698793 UTR G T New variant
(dbSNP ss
315790499)
NA 1-3 T/T T/T T/T T/T T/T T/T NA
16 54698788 UTR C T New variant
(dbSNP ss
315790500)
Transcription
regulatory (score
85.4)
1-3 T/T T/T T/T C/C C/C C/C Conserved in 7/10
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6Table 2 PTPN22 sequence variants identified by sequencing genomic DNA from three atopic and three non-atopic WHWTs. (Continued)
17 54698729 UTR T C New variant
(dbSNP ss
315790501)
NA 1-3 C/C C/C C/C C/C C/C C/C NA
18 54698473 UTR G T New variant
(dbSNP ss
315790502)
NA 0 T/T T/T T/T G/G G/T G/G Conserved in 9/10
Sequence variants with a predicted medium to high disease-associated functional effect, with strongly conserved sequence across 10 mammals (dog, human, pig, horse, mouse, rat, cattle, chimpanzee, gorilla and
orangutan) and differential distribution between atopic and non-atopic dogs are underlined (Sequence variant identities 1, 2, 11, 13 and 16)
areverse strand;
bbased on the 1.5× poodle genome (version 1) and the boxer 7.6× whole-genome sequences (CanFam2.0), accessed in March 2010 from http://www.ncbi.nlm.nih.gov and http://genome.ucsc.edu;
cas
predicted by FASTSNP [5]; disease-risk possibilities are 0 (no potential functional risk), 1 (very low risk), 2 (low risk), 3 (medium), 4 (high risk) and 5 (very high risk); FASTSNP provides a “risk score” for each SNP based
on its putative biological function;
danalyzed following genomic alignment of flanking regions containing the genetic variants in 10 possible species (dog, human, pig, horse, mouse, rat, cattle, chimpanzee, gorilla
and orangutan); UTR: untranslated region (DNA); NA: not accessed; del: nucleotide deletion
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6product 8), 57°C (3 and 14), 58°C (7, 10 and 13), 64°C
(5) or 60°C (remaining products) annealing tempera-
tures. PCR products were purified with MinElute PCR
Purification Kit (QIAGEN Pty Ltd, Doncaster, Vic, Aus-
tralia), and bi-directionally sequenced at the Australian
Equine Genetics Research Centre using 0.5 μM( P C R
p r o d u c t3 ,4 ,5 ,1 2 ,1 4 )o r1μM (remaining PCR pro-
ducts) of forward and reverse amplification primers and
0.5 μM of internal sequencing primers (Table 1), and
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA). Primers were sup-
plied by GeneWorks (Hindmarsh, SA, Australia).
Sequencing protocol was as recommended by the manu-
facturer, except annealing temperatures for PCR pro-
ducts 3, 9 and 11 were 50°C and 60°C for PCR products
4 and 5.
Sequence data were analyzed with ChromasPro v1.5
(Technylisium, Tewantin, Qld, Australia) and compared
with the 1.5× poodle (version 1) and the boxer 7.6×
whole-genome sequences (CanFam2.0). Among 18 var-
iants identified [14], five variants showed a medium to
high disease-associated risk as predicted by FASTSNP
[15] and Mutation Taster [16]; three single-nucleotide
polymorphisms (SNPs) in a predicted regulatory region
of the gene, one synonymous SNP, and a variable
sequence repeat in a predicted splice site (Table 2).
These variants formed five different haplotypes (Table 3).
There were no recombinant events within this 12.6 Kb
interval.
Variant sequence repeat c.2137-20 T(17_22) (Figure 1)
has not been previously reported in dogs or other spe-
cies and was bioinformatically predicted to have indirect
structural effects on PTPN22. Comparable intronic
repeat variations might interfere with normal gene
expression [17-19] and have been associated with alter-
native splicing and disease in humans [20-23]. Thus,
fluorescently labelled, amplified-fragment length geno-
typing of this variant was performed in 72 WHWTs,
including 54 dogs from the GWAS. Primers and PCR
conditions for amplificati o no fP C Rp r o d u c t1 1w e r e
used. Genotyping was performed on a 3130xl Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA)
and analyzed using Genemapper (Applied Biosystems,
Foster City, CA, USA). SIB-PAIR [24] showed no signifi-
cant evidence for allelic association between this variant
and the trait (gene-dropping simulation method, P =
0.01). Large scale genotyping and complementary geno-
mic and proteomic assays would be required to assess
any potential effect of the remaining genetic variants in
PTPN22.
Availability of supporting data
The data set supporting the results of this article is
available in the National Center for Biotechnology Infor-
mation Reference Assembly dbSNP repository, http://
www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi?
handle=O_LEARY_ATOPY.
Table 3 Haplotypes constructed using 18 genetic variants of PTPN22
Haplotype
a Number of chromosomes
Atopic dogs Non-atopic dogs
A C-del-G-T-T-T-del-A-C-A-C-C-variant
b-C-T-T-C-T 4/6 0/6
B T-A-A-C-C-G-del-A-T-G-C-T-wild
c-C-T-T-C-T 2/6 0/6
C C-A-G-C-C-A-del-A-C-G-T-T-wild
c-T-T-C-C-T 0/6 4/6
D C-A-G-C-C-A-del-A-C-G-T-C-wild
c-T-T-C-C-G 0/6 1/6
E C-del-G-T-T-G-del-A-C-A-C-T-variant
c-T-T-C-C-T 0/6 1/6
amaximum-likelihood (Log likelihood = - 108.87) haplotype assignment for the dogs as predicted by Superlink [7];
b22-T repeat allele;
c17-T repeat allele; del:
nucleotide deletion
54709877 AAGAATTAMTGAATATATCACTATATATAACCCAAAGGCTTAAAAAGCTATGCAACAAAA 54709818 
54709817 CTGTTTTTTTTTTTTTTTTTAAGGTATGCAGGCTCAGTCTATAGAGACTTCTTCTACTAG 54709758 
54709757 CTGTCCTAGTACCATGGAAAATTCAACATCTTCAAAGCAGACATTAAAGACTCCTGGAAA 54709698 
54709697 AAGTTTCACAAGGACTAAGGTAAAGAAGATGGGAGTTTTAAGAAATATGCCAGAGTCTTT 54709638 
54709637 CTGTTTCTGAAGGTGTTCACACTCCCTGCCTCCCCTGCTGCCAGAATCAGGATGGAAATT 54709578 
Figure 1 Relative location of the variant sequence repeat c.2137-20 T(17_22) in canine PTPN22. Exons in the gene are marked in yellow,
variants annotated in web-based databases are in green and the new intronic variant identified by sequencing in three atopic and three non-
atopic WHWTs is highlighted in pink. Line numbering is relative to coordinate system.
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